2025年欧洲肿瘤内科学会(ESMO)大会于10月17日至21日在德国柏林召开。本次大会,由天津市肿瘤医院黄鼎智教授等开展的一项“HRS-7058(一种KRAS G12C抑制剂)用于KRAS G12C突变晚期实体瘤:一项I期、多中心、首次人体研究”以口头报告形式公布(摘要号:914O)[1]。研究结果显示,HRS-7058在KRAS G12C突变晚期实体瘤中具有可控的安全性和有前景的抗肿瘤活性。...
Source Link2025年欧洲肿瘤内科学会(ESMO)大会于10月17日至21日在德国柏林召开。本次大会,由天津市肿瘤医院黄鼎智教授等开展的一项“HRS-7058(一种KRAS G12C抑制剂)用于KRAS G12C突变晚期实体瘤:一项I期、多中心、首次人体研究”以口头报告形式公布(摘要号:914O)[1]。研究结果显示,HRS-7058在KRAS G12C突变晚期实体瘤中具有可控的安全性和有前景的抗肿瘤活性。...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.